Heart-Saving hope for rare cancer patients in major trial
NCT ID NCT04810091
Summary
This study is testing if adding a drug called telotristat ethyl to standard hormone therapy better protects the heart in patients with advanced neuroendocrine tumors. About 80 patients will be randomly assigned to receive either the new drug combination or a placebo with standard therapy for six months. Researchers will measure changes in heart health markers, walking ability, and quality of life to see which treatment works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.